Clinical trial
A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease
NCT05139719 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 15, 2023
- Completion date
- December 31, 2026
- Enrollment
- 110 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
progressive fibrosing interstitial lung disease (pf-ild) / progressive pulmonary fibrosis (ppf)